x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Pharma and BioTech Daily

Pharma and BioTech News

This podcast aims to bring you a daily summary of the most relevant news in Pharma and BioTech. Check our website at: https://www.buzzsprout.com/2189790

news tech news

All Episodes

2:08

Pharma and Biotech Daily: Keeping You Informed on FDA...

Pharma and BioTech Daily ·

2025/10/13

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ##FDA Approves New Cancer TreatmentThe FDA has approved a new cancer treatment that has shown promising results in clinical trials. This treatment is expected to provide a new option for patients who have not responded well to traditional therapies. ##Drug Company Announces Major Breakthrough in Alzheimer's ResearchA drug company has announced a major breakthro...

en-us

4:30

Week in Review - October 10, 2025

Pharma and BioTech Daily ·

2025/10/12

his Week in Review covers 5 episodes from October 06 to October 10, featuring major developments in the pharmaceutical and biotech industries. Episodes included: 1. Pharma and Biotech Daily: Novo's Acquisition, FDA Breakthroughs, and Industry Updates 2. Pharma and Biotech Daily: Top Stories in the Industry from Zenas to Lilly 3. Pharma and Biotech Daily: Tariff Impact, Promising Trials, and Industry Leaders 4. Pharma and Biotech Daily: The Latest in Cell and Gene Therapy, M&A Activity, an...

en-us

0:51

Pharma and Biotech Daily: Novo's Acquisition, FDA...

Pharma and BioTech Daily ·

2025/10/10

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.Novo has recently completed the acquisition of Akero in a deal valued at up to $5.2 billion. This acquisition adds Akero's efruxifermin to Novo's already impressive portfolio. The FDA breakthrough drugs continue to show promise, with nearly three quarters of designated drugs being approved, especially in the rare disease and cancer categories.In other news, ther...

en-us

1:46

Pharma and Biotech Daily: Top Stories in the Industry...

Pharma and BioTech Daily ·

2025/10/09

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Zenas has made a $2 billion bet on autoimmune diseases with Chinese firm InnoCare, focusing on the development of orelabrutinib for multiple sclerosis. Former FDA director Peter Marks has joined Eli Lilly, marking the company's continued push in China. Sanofi's advancements in radiopharma, Boehringer Ingelheim's breakthrough in idiopathic pulmonary fibrosis, and Taked...

en-us

1:30

Pharma and Biotech Daily: Tariff Impact, Promising...

Pharma and BioTech Daily ·

2025/10/08

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.A new survey from CRB shows that most life sciences companies, particularly smaller biotechs, are not planning new investments in response to tariffs. The majority of manufacturing initiatives in the U.S. made in response to tariffs are coming from big pharma companies. Sky Bioscience's CB1 inhibitor, Nimacimab, showed promising weight-loss results when combined wit...

en-us

1:49

Pharma and Biotech Daily: The Latest in Cell and Gene...

Pharma and BioTech Daily ·

2025/10/07

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Chiesi has entered a $2.1 billion collaboration with Arbor to develop a gene therapy for primary hyperoxaluria type 1. AstraZeneca continues to invest in AI partnerships, FDA lifts clinical hold on Neurizon's ALS drug, and the cell and gene therapy field faces challenges and opportunities at the Meeting on the Mesa event. CDC adopts ACIP recommendations, FDA's manufac...

en-us

0:51

The Essential Updates in Pharma and Biotech: Your...

Pharma and BioTech Daily ·

2025/10/06

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Former NIAID director Jeanne Marrazzo was fired after filing a whistleblower report, alleging retaliation. The FDA's new cell and gene therapy guidances have been well-received for streamlining therapies. In other news, CMS has finalized stronger protections for orphan drugs, and Amgen's Repatha has shown positive results in preventing heart disease. Lotte Biologics ...

en-us

0:56

Pharma and Biotech Daily: Top Stories from the Industry

Pharma and BioTech Daily ·

2025/10/03

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. President Trump has once again delayed the imposition of 100% tariffs on pharmaceuticals, with preparations now set to begin on October 1. Halozyme's acquisition of Elektrofi for $900 million has brought two major pharmaceutical partners together, while Takeda is exiting the cell therapy sector and laying off 137 employees. Roche's $3.5 billion takeover of 89bio wa...

en-us

1:48

Pharma and Biotech Daily: Navigating Industry Shifts...

Pharma and BioTech Daily ·

2025/10/02

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry...

en-us

1:12

Pharma and Biotech Daily: Metsera's Mid-Stage...

Pharma and BioTech Daily ·

2025/10/01

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's mid-stage obesity drug, met-097i, has shown "very encouraging" efficacy, supporting Pfizer's proposed $4.9 billion buyout of the company. The drug's performance is seen as positive by BMO Capital Markets. In other news, drug manufacturers are increasingly utilizing artificial intelligence throughout the drug production process, moving from using AI for sp...

en-us

1:52

Pharma and Biotech Daily: Genmab Acquires Merus, GSK...

Pharma and BioTech Daily ·

2025/09/30

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next yea...

en-us

1:11

Pharma and Biotech Daily: Trump's Tariff Deadline,...

Pharma and BioTech Daily ·

2025/09/29

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump has announced a 100% tariff deadline for pharmaceutical companies starting on October 1. However, companies that have already begun construction on manufacturing facilities in the U.S. are exempt from these tariffs. This move is part of the administration's efforts to lower drug prices and improve access to treatments for patients.In other news, Crin...

en-us

0:47

Promising Results for Atebimetinib in Pancreatic...

Pharma and BioTech Daily ·

2025/09/26

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.## Immuneering's drug atebimetinib has shown promising results in doubling overall survival in pancreatic cancer patients after nine months. Truist analysts have deemed the results encouraging, although some unknowns remain in the data. Immuneering plans to initiate a registrational trial for atebimetinib later this year. ## In other news, Lilly has halted a mid...

en-us

1:53

The Rise and Challenges of Chinese Biotech: A Global...

Pharma and BioTech Daily ·

2025/09/25

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Uniqure's gene therapy for Huntington's disease, AMT-130, has shown promising results in a 3-year study, slowing disease progression by 75%. If approved, it would be the first genetic treatment for Huntington's. Meanwhile, Acadia Pharmaceuticals has discontinued a Prader-Willi drug after a late-stage failure. Biogen received an unexpected FDA rejection for a high dose...

en-us

0:48

Pharma and Biotech Daily: FDA Revives Drug for...

Pharma and BioTech Daily ·

2025/09/24

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has revived a long-dormant drug from GlaxoSmithKline as a potential treatment for autism. The agency also mentioned the potential link between the use of Tylenol and other acetaminophen products during pregnancy and neurological and developmental defects in children. In other news, Scholar Rock's spinal muscular atrophy drug faced manufacturing site issues, w...

en-us

0:55

Pharma and Biotech Daily: Pfizer's Comeback, FDA...

Pharma and BioTech Daily ·

2025/09/23

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Pfizer has made a comeback in the obesity market with the acquisition of Metsera for $4.9 billion, rejuvenating its portfolio after facing challenges with three discontinued assets. Meanwhile, Stealth BioTherapeutics has received expedited FDA approval for the first-ever treatment for Barth syndrome, and Sanofi's decision on their oral multiple sclerosis drug has b...

en-us

0:55

Pharma & Biotech Daily: ACIP Updates, Stock Crashes,...

Pharma and BioTech Daily ·

2025/09/22

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The Advisory Committee on Immunization Practices (ACIP) has changed its recommendations for the MMRV vaccine for children under four, advising that the measles, mumps, rubella (MMR) vaccine be administered separately from the chickenpox vaccine. The committee is also expected to make changes to the childhood schedule for hepatitis B and COVID-19 vaccines. Replimune's...

en-us

1:53

Navigating Uncertainty: Updates from the Pharma and...

Pharma and BioTech Daily ·

2025/09/19

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has made a significant move in the pharmaceutical industry by acquiring 89bio for $3.5 billion, with a contingent value right of $6 per share. The acquisition includes pegozafermin, an analog in late-stage development for metabolic dysfunction-associated steatohepatitis. Meanwhile, former CDC director Susan Monarez spoke to the Senate about her firing, allegin...

en-us

1:14

Pharma and Biotech Daily: Navigating the...

Pharma and BioTech Daily ·

2025/09/18

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly's oral weight loss pill, orfoglipron, has faced challenges in meeting expectations, possibly due to an over-representation of males and Hispanic patients in the phase III study. The company is now presenting detailed late-stage data to paint a competitive profile for the drug. Meanwhile, the FDA has targeted Lilly and Novo Nordisk for downplaying risks of th...

en-us

0:58

Pharma and Biotech Daily: Novo's Breakthrough Drug,...

Pharma and BioTech Daily ·

2025/09/17

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo's amylin analog drug, cagrilintide, has shown a significant 11.8% weight loss in a phase III trial, with improved safety data to address past tolerability issues. The FDA is set to make a decision on the drug, with significant stakes for the company and the Barth Syndrome community. Additionally, Sarepta's DMD gene therapy is still being prescribed by doctors ...

en-us

425 results

Similar Podcasts

Expres Ráno

Expres FM

PBS News Hour - Full Show

PBS NewsHour

CD Voice

China Daily

Israel Today: Ongoing War Report

Noa Levi

Jeffrey Epstein: The Coverup Chronicles

Bobby Capucci